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Abstract
The stable infection of host macrophages by Mycobacterium tuberculosis (Mtb) involves, and depends on, the attenuation of
the diverse microbicidal responses mounted by the host cell. This is primarily achieved through targeted perturbations of
the host cellular signaling machinery. Therefore, in view of the dependency of the pathogen on host molecules for its
intracellular survival, we wanted to test whether targeting such factors could provide an alternate route for the therapeutic
management of tuberculosis. To first identify components of the host signaling machinery that regulate intracellular
survival of Mtb, we performed an siRNA screen against all known kinases and phosphatases in murine macrophages
infected with the virulent strain, H37Rv. Several validated targets could be identified by this method where silencing led
either to a significant decrease, or enhancement in the intracellular mycobacterial load. To further resolve the functional
relevance of these targets, we also screened against these identified targets in cells infected with different strains of
multiple drug-resistant mycobacteria which differed in terms of their intracellular growth properties. The results obtained
subsequently allowed us to filter the core set of host regulatory molecules that functioned independently of the phenotypic
variations exhibited by the pathogen. Then, using a combination of both in vitro and in vivo experimentation, we could
demonstrate that at least some of these host factors provide attractive targets for anti-TB drug development. These results
provide a ‘‘proof-of-concept’’ demonstration that targeting host factors subverted by intracellular Mtb provides an attractive
and feasible strategy for the development of anti-tuberculosis drugs. Importantly, our findings also emphasize the
advantage of such an approach by establishing its equal applicability to infections with Mtb strains exhibiting a range of
phenotypic diversifications, including multiple drug-resistance. Thus the host factors identified here may potentially be
exploited for the development of anti-tuberculosis drugs.
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Introduction
Successful parasitization of macrophages by Mycobacterium
tuberculosis (Mtb) reflects the equilibrium between host and
pathogen, which is established and maintained through the
modulation of macrophage-signaling mechanisms. This leads to
the attenuation of several cellular processes that include fusion of
phagosomes with lysosomes, antigen presentation, apoptosis, and
the bactericidal responses initiated by the macrophage [1,2,3].
This attenuation represents the outcome of a dynamic process
wherein bacterial molecules interfere with the signaling machinery
of the host cell. Although a detailed picture is yet unavailable,
many bacterial mediators of virulence have been identified and the
strategies employed by them are currently being elucidated
[4,5,6,7,8,9]. The emerging theme, however, suggests that
pathogen-directed manipulation of host processes is achieved
through targeted perturbations in the host cell-signaling network
[10,11,12,13,14]. It is these perturbations that then reorient the
cellular response to support intracellular survival and growth of
Mtb. A better understanding of the mechanisms involved in these
perturbations should, therefore, greatly aid current efforts at
developing new drugs for tuberculosis (TB).
We undertook this study to identify components of the host cell
signaling machinery that are important for regulating an Mtb
infection. For this, we performed an siRNA screen against all
kinases and phosphatases, in mouse macrophages infected with a
virulent strain of Mtb (H37Rv). Such experiments identified
several host molecules that were involved either in facilitating, or
suppressing, the intracellular infection. By then applying a filter of
phenotypic variations, at the level of both drug resistance and
intracellular growth properties, we could further distinguish those
host molecules that regulated intracellular pathogen load in an
Mtb strain-independent manner. A combination of in vitro and in
vivo experimental approaches subsequently enabled us to establish
that targeting such host factors indeed provides an attractive
alternate strategy for the development of anti-TB drugs.
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Importantly, our results suggest that such an approach could also
potentially address the problem of multiple drug resistance in TB
infections.
Results
Identifying host proteins that regulate Mtb survival in the
macrophage
The siRNA library employed in the primary screen consisted of
a pool of two siRNAs per target gene, and the targets included 744
kinases and 288 phosphatases. Cells of the murine macrophage
line, J774.1, were first infected with a virulent strain of Mtb
(H37Rv), and then transfected with individual target-specific
siRNA. The siRNA transfection was performed after infection of
cells to ensure an un-hindered uptake of pathogen and, therefore,
to select for only those host proteins that were involved in the
maintenance of an established infection. The effect of specific
silencing on intracellular mycobacterial load was then determined
from cell lysates in terms of the colony forming units (CFU)
subsequently obtained (Methods).
At one level, silencing of several macrophage proteins resulted
in a significant decrease in titers of the intracellular bacteria
obtained (Table S1). However, there were also many instances
where a targeted protein-knockdown led to a marked increase in
mycobacterial levels (Table S1). Selection of only those effects as
significant, where intracellular bacterial load varied by greater
than two standard deviations (2SD) of the mean CFU values
obtained for the control wells (Methods), identified 203 target-
specific siRNAs (Table S1). To next filter out any non-specificity
arising from ‘off-target’ effects of the siRNA, we performed a
second screen where the primary ‘hits’ were now silenced with an
alternate pool of siRNAs (Methods). Although such an approach
likely leads to an increased number of false negatives due to
differences in silencing efficiency between the two target-specific
siRNA pools, a high degree of confidence is – nonetheless -
associated with any reproducible effects that are consequently
obtained. This procedure led to a further reduction in the number
of significant targets to forty one (Table S1). Then, as the final
validation step, we tested whether these target-specific siRNA
pools had any effect on the viability of either un-infected, or
infected, J774.1 cells over the time course of our experiment (Text
S1). In neither of these cases, however, did any of the siRNA pools
negatively influence cell viability to an extent that was greater than
1.5 SD of the mean values obtained for the control wells (Table
S2). Therefore, these forty one targets identified by the
corresponding set of siRNA pools were taken as the validated
target group. The effect of silencing of each of these on the
intracellular bacterial load is shown in Figure 1A, whereas
Figure 1B confirms that the siRNA pools used in the primary
and in the validation exercise both yielded effects that were greater
than 2SD of the mean CFU value obtained for the corresponding
control wells. As is evident, the effects of target-suppression ranged
from a near complete elimination of the infection, to a significant
enhancement in intracellular bacterial titers (Fig. 1A). Thus,
adaptation of mycobacteria in the intracellular milieu likely
involves both facilitating and inhibitory contributions from some
of the components of the host cell signaling machinery. The
validated targets are listed in Table 1, which also includes a gene
ontology-based classification of their functional roles. A more
detailed description of these genes and their known association
with disease and other cellular functions is provided in Table S3.
We next took four representative examples from each of the two
distinct groups in Figure 1, and examined – by confocal
microscopy - whether the observed modulation in CFU values
also correlated with alterations in the level of mycobacteria
localization, within the lysosome of the host cell. Interestingly, in
infected cells treated with non-silencing siRNA, the co-localization
of H37Rv with acidified lysosomes could be detected – with a
mean overlap coefficient of 0.20 - in only a little over 50% of the
cells, (Fig. 2). In contrast, those instances where silencing yielded a
reduced CFU count in Figure 1 (Csnk1d, Adrbk1, Prkacb, and TgfbrI),
showed a marked increase in mycobacterial co-localization with
acidified lysozomes, both at the level of individual cells, as well as
at that of the proportion of cells showing such co-localization
(Fig. 2). On the other hand, values for both of these parameters
were significantly reduced for the cases (Wee1, Abl1, Dgkz, and
Chek1) where target gene silencing resulted in an increase in the
CFU counts (Fig. 2, compare with Fig. 1).
Thus, at least for the representative cases shown in Figure 2, the
observed alterations in the CFU counts constitute a true reflection
of shifts in the fate of the intracellular bacteria. Finally, an
examination of the gene expression profiles both in un-infected
J774.1 cells, and in cells infected with H37Rv either for 16h, 48h,
or 96h, confirmed that the genes coding for all of the proteins
listed in Figure 1 were indeed expressed in uninfected cells, albeit
to different levels. Further, expression levels of thirty-four of these
remained largely unaffected following infection of the cells (Table
S4).
Identification of common host-derived protein targets
for MDR-Mtb
We next asked whether the proteins identified against H37Rv in
Figure 1 would also be relevant for infections with field isolates of
Mtb, particularly for those exhibiting multiple drug resistance
(MDR). To address this we took two independent clinical isolates
of MDR-Mtb, each displaying a distinct drug-sensitivity profile
(Fig. 3A). The relative growth rates of these two isolates with, that
of H37Rv, was first compared both in extracellular cultures, as
well as in infected cells. Interestingly, while all the three isolates
displayed similar growth properties under extracellular conditions
Author Summary
The adaptation of Mycobacterium tuberculosis (Mtb)
involves dynamic interactions with the molecular compo-
nents of the host cellular machinery. Therefore, targeting
relevant host factors may provide an alternate approach
for the chemotherapy of tuberculosis (TB). To test this, we
first performed an siRNA screen targeting all known
kinases and phosphatases in murine macrophages infect-
ed with a virulent strain of Mtb. A subsequent validation of
this screen then identified several host molecules whose
depletion severely affected the intracellular survival of
mycobacteria. We also then screened against the identified
host targets in cells infected with independent isolates of
MDR-Mtb. This exercise identified those host molecules
that were indispensable for supporting infection, indepen-
dent of the phenotypic variations exhibited by the
pathogen. Then, by using a pharmacological inhibitor that
simultaneously targeted two of these molecules, we were
able to demonstrate clearance of both drug-sensitive and
drug-resistant strains of Mtb from infected cells. Impor-
tantly, this inhibitor was also effective in mice infected
with the virulent strain of Mtb. Thus, in addition to
demonstrating the feasibility of targeting host molecules
involved in supporting intracellular persistence of patho-
gen for TB therapy, our studies also identify several such
molecules that may be exploited for the purposes of drug
development.
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(Fig. 3B) these, however, differed markedly when measured within
infected J774.1 cells (Fig. 3C). In this latter experiment, a
progressive increase in CFU counts was obtained for H37Rv over
the time course studied whereas the MDR strain 1934 displayed
an accelerated growth rate between the 48h and the 90h time
points. In stark contrast, however, virtually no increase in bacterial
titers could be observed for the other MDR strain, JAL2261, at
any of the time points studied. A reduced intracellular growth rate
for JAL2261, in comparison with the other two strains, was also
similarly observed in primary murine macrophages (Fig. S1). Thus
the three Mtb strains studied exhibit diverse growth properties
within J774.1 cells.
We next infected J774.1 cells with each of the MDR-Mtb strains
and tested for the effects of treatment with the siRNAs described in
Figure 1. The results obtained are shown in Figure 4. While the
overall profiles obtained for both 1934 and JAL2261 show
distinctions from that for H37Rv, some overlaps were –
nonetheless – clearly evident. This was particularly true in the
case of 1934 where, of the 41 targets tested, comparable effects of
target silencing (i.e. within a 30% deviation) on both 1934 and
H37Rv were observed in 31 cases (Fig. 4). The majority of these
instances (25 of 31) represented the group wherein siRNA
treatment yielded a reduction in the intracellular bacterial load,
whereas a relatively poorer correspondence was obtained for the
group where increased bacterial titers were observed (6 out of 11;
Fig. 4). Discrepant results were obtained for Trpm7 and Prkag3
although the cause for this is presently unclear.
In contrast to 1934, a comparison between the results obtained
for JAL2261 and H37Rv revealed a significantly reduced overlap,
with the similarity in effects being restricted to only 11 instances of
siRNA treatment (Fig. 4). Further, all of these cases derived
exclusively from the subset involving a consequent reduction in the
level of the intracellular mycobacteria (Fig. 4). This reduced
sensitivity of JAL2261, to perturbations in host protein levels, is
probably consistent with the fact that it exists in a non-dividing, or
slow-dividing, state within the host cells. Thus the results in
Figure 4 identify 11 host targets, whose depletion uniformly led to
a reduction in intracellular load of all the three Mtb strains tested.
Host factors regulating intracellular Mtb levels provide
attractive targets for drug development
The identification of host factors commonly implicated in
regulating intracellular levels of all the three Mtb strains tested
raised the possibility that at least some of these may serve as targets
for the development of drugs against both drug-sensitive and drug-
resistant forms of Mtb infection. At least at the level of ‘proof of
principle’, employing existing chemical inhibitors of any of these
targets can readily test such a possibility. Therefore, for the present
purposes, we chose to examine the effects of inhibition of TGF-b
type-1 receptor (TGFbRI). Our choice of this target was based on
the results of our microarray experiments which indicated that
transcript levels of both this receptor, as well as that of its isoform
TGF-b type-2 receptor (TGFbRII) were significantly increased in
cells infected with Mtb for 16h, although these levels then returned
to their basal values at the later times (Fig. 5A). Further, expression
of the genes for the cognate ligands, TGFbI and TGFbII were also
induced (Fig. 5A). Here, although the extent of induction of
TGFbI was not significant (i.e. below the cut-off threshold) this,
nonetheless, translated into a significant increase in the levels of
this cytokine in the culture supernatants (Fig. 5B). It was, therefore,
Figure 1. Validation of host-specific proteins involved in regulating Mtb infection. Panel A shows the results obtained for the confirmed
targets either in the primary (black squares), or the validation screen (red circles). In view of the inherent differences between the siRNA pools in the
two screens, a 50% effect on bacterial load was employed as the cut-off for validation in the latter screen. The scatter plot compares the similarity
between the two screens. The Y-axis gives the percent reduction in CFUs obtained relative to the control values (see Text), where a negative value
indicates an increase in intracellular bacterial load. These values are the average of 4 different replicates for each screen (Table S1). The two dashed
lines in orange and blue indicate the respective cut-off values taken for considering either a decrease, or an increase, in bacterial levels as significant.
Panel B shows a scatter plot comparing the fold deviation of the mean values for the individual points in Figure 1A, relative to SD of the mean CFU
values for the corresponding controls.
doi:10.1371/journal.ppat.1000839.g001
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logical to infer that secretion of TGFb by infected cells would lead
to the corresponding activation of its receptor, either through
autocrine or paracrine mechanisms. Further, at least based on the
results of our siRNA screen, it seemed likely that this activation
was somehow relevant for maintenance of the intracellular
pathogen.
To experimentally verify the inferred role for TGFb-dependent
activation of its receptor, we added neutralizing anti-TGFb
antibodies to cultures of H37Rv-infected J774 cells and then
determined its consequent effect in terms of the mycobacterial
CFUs obtained. Figure 5C shows that addition of anti-TGFb
antibodies resulted in a substantial reduction in intracellular Mtb
load, thus confirming the relevance of this cytokine in regulating
intracellular Mtb. To further establish this, we also performed
experiments in mice that were transgenic for the dominant
negative form of the TGFb receptor type II (TGFbRIIDN).
Table 1. Functional Classes of ‘Hits’.
Gene Accession GeneSymbol GO Classes
NM_007377 Aatk Integral to membrane, Protein serine/threonine kinase activity
NM_009594 Abl1 Actin cytoskeletal organization, Magnesium ion binding
NM_133770 ADCK4 Protein serine/threonine kinase activity, Transferase acivity
NM_134079 Adk dATP biosynthetic process, Transferase activity
NM_130863 Adrbk1 G-PCR tyrosine kinase activity, Protein serine/threonine kinase activity
NM_015804 Atp11a Phospholipid transport, ATP biosynthetic process
NM_029097 Atp13a2 ATP biosynthetic process, Cation Transport
NM_144921 Atp1a3 Ion Transport, ATP Biosynthesis
NM_175025 Atp2c1 Calcium ion transport, Golgi Apparatus
NM_013482 BTK I-Kappab kinase/ NFKappab cascade, Cytoplasmic Vesicle
NM_001025438 CaMK2d Calmodulin Binding, Calcium Ion Transport
NM_007631 Ccnd1 Endoplasmic reticulum unfolded protein response, Wnt Signaling
NM_007658 Cdc25a Hydrolase activity, Protein tyrosine phosphatase activity
NM_023117 Cdc25b Cytoskeleton, Protein tyrosine phosphatase activity
NM_009860 Cdc25c Hydrolase activity, Protein tyrosine phosphatase activity
NM_194444 CDK10 ATP binding, Transferase Activity
NM_007691 Chek1 Cytoskeleton, Protein serine/threonine kinase activity
NM_027874 Csnk1d Wnt receptor signaling pathway, Protein serine/threonine kinase activity
NM_013767 Csnk1e Wnt receptor signaling pathway, Protein serine/threonine kinase activity
NM_007828 DAPK3 Induction of apoptosis, Protein serine/threonine kinase activity
NM_138306 Dgkz Diacylglycerol Kinase activity, Negetive regulation of Ras protein signal transduction
NM_023173 Dusp12 Protein tyrosine/serine/threonine phosphatase activity, Metal ion binding
NM_019819 Dusp14 Protein tyrosine/serine/threonine phosphatase activity, Hydrolase Activity
NM_026268 Dusp6 Protein tyrosine/serine/threonine phosphatase activity, Hydrolase Activity
NM_178676 Entpd3 Hydrolase Activity, 59- Nucleotidase Activity
NM_008363 IRAK1 TLR2/4 signaling pathway, Response to LPS, Peptidoglycan
NM_181593 Itpkc Calmodulin Binding, Inositol triphosphate 3-Kinase activity
NM_025730 LRRK2 Memberane Raft, Trans golgi network
NM_011948 MAP3K4 Map kinase kinase kinase activity, Metal ion binding
NM_008825 Pfkfb2 Fructose Metabolic Process, Hydrolase activity
XM_134059 Ppapdc1 Hydrolase activity, Integral to membrane
NM_011100 Prkacb G-protein signaling, Coupled to cAMP nucleotide second messenger, Transferase activity
NM_153744 Prkag3 Lipid Biosynthetic Process, Glycogen Biosynthetic Process
NM_016795 SRPK1 ATP binding, Protein serine/threonine kinase activity
NM_009370 TGFbR1 Protein Serine/ Threonine Kinase Activity, TGFb Receptor Activity
NM_011587 TIE1 Receptor Activity, ATP binding
NM_021450 Trpm7 Calcium ion transport, Actin Binding
NM_183099 TSSK5 Protein Serine/Threonine Kinase Activty, Metal Ion Binding
NM_026765 Uckl1 Metabolic Process, Phospho Transferase Activity
NM_009469 ULK1 Regulation of autophagy, Autophagic Vacuole
NM_009516 Wee1 Protein tyrosine/serine/threonine kinase activity, Metal Ion Binding
doi:10.1371/journal.ppat.1000839.t001
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Although our screen identified TGFb receptor type-I as the hit,
signaling through TGFb1 involves the formation of an active
heteromeric complex between the type-I and type-II receptors.
Thus, binding of TGFb to the type-II receptor leads to the
recruitment and phosphorylation of the type-I receptor, with the
subsequent activation of downstream pathways [15]. Consequent-
Figure 2. Alterations in levels of host-specific proteins influence the fate of intracellular mycobacteria. Figure shows the effect of the
indicated target-specific siRNAs, or of non-silencing siRNA (GFP-specific, Control), on the extent of co-localization of mycobacteria with acidified
lysosomes. Mycobacteria were labeled with the lipophilic dye PKH67 (green) prior to infection. Infected cells were then monitored at 72 hours by
confocal laser scanning microscopy to determine the extent of co-localization of mycobacteria with acidified lysosomes (panel A), and the percent of
cells in which such a co-localization was visible (panel B). Acidified lysosomes were stained with Lysotracker (red) (see Methods and Text S1). In panel
A, the yellow color in the ‘merge’ signifies co-localization of the two. The numbers in panel B give both the overlap coefficient of the bacteria with the
lysotracker, as well as the percent of cells in which this co-localization was detected. More than 40 infected cells (i.e. positive for fluorescent
mycobacteria) were examined in slides generated from three separate experiments and the values in panel B represent the mean 6S.D. Further, the
values for both parameters were found to be significantly different at p,0.005. As is evident, both the overlap coefficient and the fraction of cells
with mycobacteria in acidified lysosomes were higher than control values following depletion either of ADRBK1, CSNK1d, TGFbRI, or PRKACB. In
contrast, these values were low when ABL1, CHEK1, DGKZ or WEE1 was depleted. This correlates well with the corresponding results obtained in terms
of the CFU values shown in Figure 1. The extent of siRNA-mediated silencing obtained for each of these target proteins is shown in Figure S3.
doi:10.1371/journal.ppat.1000839.g002
Figure 3. Intracellular growth properties of H37Rv and the two MDR isolates. Panel A depicts the sensitivity profile of the clinical isolates
against the four standard, first-line, anti-mycobacterial drugs (S, sensitive; R, resistant). Panels B and C show the growth properties of H37Rv, and the
two clinical strains either in extracellular cultures (panel B), or in infected J774.1 cells (Panel C). For the former, mycobacteria were seeded in culture
medium at 26107/ml and the growth monitored by measuring absorbance at 600 nm. Values obtained in the log phase of growth are shown here.
For Panel C, cells were separately infected with each of the three strains and CFU counts determined in lysates obtained at 24, 48, and 96 hrs later
(Methods). A parallel set of infected cells was also taken for determining the cell viability, by an MTT assay, at each of these time points. Values
presented are the mean (6 S.D.) of triplicate measurements of CFU counts, as a function of the absorbance obtained in the MTT assay at each of the
time points. The corresponding growth rate of these strains in primary mouse macrophages is shown in Figure S1.
doi:10.1371/journal.ppat.1000839.g003
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ly, TGFb-dependent signaling would be similarly affected by
either silencing the type-1 receptor, or over–expressing the
dominant negative form of the type-II receptor. As shown in
Figure 5D, TGFbRIIDN mice were significantly more resistant to
an aerosol route of infection with H37Rv, than their wild type
counterparts. This was consistent with the fact that macrophages
isolated from the transgenic mice indeed showed over-expression
of TGFbRIIDN (Fig. 5D). Collectively then, the results in Figure 5
provide strong experimental support for the likelihood that TGFb-
dependent activation of its receptor on macrophages is critical for
the survival of intracellular Mtb.
To inhibit TGFbRI activation, we employed the compound 4-
[4-(2,3-Dihydro-1,4-benzodioxin-6-yl)-5-(2-pyridinyl)-1H-imidia-
zol-2-yl]benzene (D4476). Our choice of this inhibitor was
guided by the fact that, in addition to TGFbRI, this compound is
also known to inhibit casein kinase 1 (CSNK1) [16,17], another
member of our validated target list in Figure 4. Interestingly,
CSNK1 also represents a downstream intermediate in the
TGFbR signaling pathway, and has been shown to regulate
both ligand-independent (i.e. basal), as well as ligand-induced
signaling processes [18]. Thus, it was anticipated that the
simultaneous inhibition of TGFbRI and one of its downstream
signaling intermediates would yield a more effective inhibition of
TGFb-dependent signaling and, therefore, a more potent effect
on intracellular Mtb levels.
Cells infected either with H37Rv, 1934, or JAL2261 were
treated with increasing doses of D4476, and the consequent effect
on intracellular pathogen load was then determined as the
Figure 4. Overlapping sensitivities of different MDR-Mtb strains to the effects of target-specific siRNA. Cells infected with either 1934,
or with JAL 2261, were screened against the target-specific siRNAs shown in Figure 1. The resulting CFUs obtained are again presented in terms of the
percent reduction obtained relative to control values, where a negative value indicates an increase in bacterial titers. The corresponding values
obtained for H37Rv are also included for the sake of comparison, and the color code used for the individual strains is indicated. Values are the mean
(6 S.D) of the total of four values obtained from two separate experiments (i.e. CFUs from two lysate dilutions per experiment).
doi:10.1371/journal.ppat.1000839.g004
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resulting CFU values obtained (Fig. 6A). A dose-dependent
decrease in mycobacterial CFUs, with increasing inhibitor
concentrations, was clearly obtained for all the three isolates
tested (Fig. 6A). Importantly, this effect was specific for the
mycobacteria and this drug displayed no toxicity towards the host
cell (Fig. 6B). In parallel studies employing confocal microscopy we
observed that treatment with the inhibitor also led to a
corresponding increase in localization of each of the mycobacterial
isolates within acidified lysosomes of the cell (Fig. 6C). This further
supports that treatment with the inhibitor leads to an enhanced
Figure 5. Mtb infection regulates levels of TGFb and its receptor in host cells. Panel A depicts the time-dependent changes in expression
levels of the cytokines TGFb1, TGFbII, and their receptors TGFbRI and TGFbRII in J774.1 cells infected with H37Rv (see Methods and Text S1). Values
were taken from the results from our gene expression analysis described in Table S4. Panel B describes the levels of TGFbI protein in the culture
supernatants of J774.1 cells infected for the indicated times with H37Rv. The concentration of this cytokine was determined using the TGFbI
Lincoplex kit (Text S1), and values are the mean 6 S.D. of three separate experiments. Panel C shows the results of an experiment where H37Rv-
infected J774 cells were cultured either in the presence (Treated) or absence (Control) of neutralizing monoclonal antibodies against TGFb (clone
1D11). This antibody neutralizes all the three isoforms of TGFb. The antibody was first added (final concentration of 0.5 mg/ml) at 12h after infection
and then replenished at every 12h thereafter, up to 72 h post-infection. At 90h post-infection cells were lysed and bacterial loads determined in terms
of the CFU values (mean 6 S.D. of three experiments). Statistical significance of the difference seen is also indicated. For the experiment in Panel D,
either wild type (Balb/C) or TGFbRIIDN (Balb/c background) mice were infected with H37Rv through the aerosol route as described in Methods. These
mice were then sacrificed at the indicated time points and mycobacterial CFUs present in the lung homogenates was determined. Values obtained at
time point are the mean (6 S.D.) of that obtained in four mice. Results shown here are from one of three separate experiments taking four mice/
group in each. For the remaining two experiments, CFU values obtained at day 60 for the wild type versus the TGFbRIIDN mice were 5.761.26105
versus 0.4260.16105 and 2.860.46105 versus 0.160.066105. The inset in the panel compares mRNA levels of TGFbRIIDN in peritoneal macrophages
(a) with that in splenic lymphocytes (b), against actin as the control for semi-quantitative comparison.
doi:10.1371/journal.ppat.1000839.g005
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Figure 6. Dual inhibition of TGFbR1 and Casein kinase eliminates Mtb from infected cells. J774.1 cells independently infected with each
of the three isolates were treated with either the vehicle only or with the indicated concentrations of D4476 (Dose). Addition was performed at 16h
and the medium containing the appropriate dose of inhibitor was refreshed every 24 h up to the 64 h time point. At the end of a total culture period
of 90h, cells were lysed and CFUs determined as described in Methods. Panel A shows the results where the CFU values from inhibitor-treated cells
are expressed as a percent of that obtained from correspondingly infected cells treated with vehicle only. Panel B shows the viability of infected
J774.1 cells obtained at the 90h time point either in the presence (light blue bars), or absence (light green bars) of 50mM D4476. In both cases, values
are the mean (6 S.D.) of three separate determinations. The p-values are indicated by the stars; *,0.05 and **,0.01. Panel C shows the results of a
parallel experiment where the extent of co-localization of PHK67-stained mycobacteria with acidified lysosomes (stained with Lysotracker) was
The Host-Dependent Survival Axis of M. tuberculosis
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clearance of the intracellular pathogen. Importantly, the effect of
D4476 addition was specific for intracellular mycobacteria, with
no significant effect on mycobacterial growth in extracellular
cultures (Fig. 6D). This confirms that the inhibitor did not directly
target Mtb. Rather it more likely interfered with the intracellular
survival mechanisms of the pathogen. Importantly, from the
standpoint of pharmacological intervention, that simultaneous
inhibition of TGFbRI and its downstream signaling intermediate
leads to a more potent effect on intracellular Mtb could be
demonstrated by comparing the relative efficacy of D4476 with
that of inhibitors specific for only either TGFbRI (LY364947 [19])
or CSNK1 (IC261, [17]) (Fig. 6E).
The inhibitory effect of D4476 on intracellular Mtb survival
could also be demonstrated in primary murine macrophages
infected with each of the three Mtb strains. Thus, consistent with
the findings in J774 cells, addition of D4476 to infected primary
macrophages resulted in enhanced co-localization of all three
mycobacterial strains with the lysosome, and also a significant
reduction in CFU count in each of these cases (Figure S1). Thus
the cumulative results in Figure 6 confirm a key role for TGFbR
signaling in regulating intracellular Mtb survival, but in a manner
that is independent of at least the spectrum of phenotypic
variations encompassed by this group of isolates.
Compound D4476 also eliminates Mtb from infected
mice
To further validate the relevance of targeting host factors, we
also examined the efficacy of D4476 in the murine model of TB
infection. For this, BALB/c mice were intravenously infected with
H37Rv and these mice were then treated with two different
concentrations of D4476. Treatment was initiated at ten days after
the infection, and included six administrations of the relevant dose
of the inhibitor (Text S1). As shown in Figure 7A, a clear reduction
in CFU counts was obtained from the lungs of infected mice
treated with D4476. Further, the magnitude of this inhibition was
sensitive to the dose of the compound with a dose of 4 nmol/g of
body weight yielding a nearly 80% reduction in CFU counts.
Similar results were also obtained in mice infected through the
aerosol route (Fig. 7B), confirming that the efficacy of D4476 was
independent of the route of infection employed. D4476-dependent
clearance of infection was also evidenced through recovery from
the infection-induced splenomegaly (Fig. 7C). Further, histochem-
ical staining of lung sections also revealed a significant reduction in
the number of epitheloid cell granulomas, and in that of acid-fast
staining bacilli, in treated versus the untreated mice (Figure 7D).
The collective results in Figure 7, therefore, demonstrate the in
vivo efficacy of D4476 in terms of eliminating an Mtb infection.
While its potency may be considered to be low we emphasize,
however, that our objective here was not to propose this
compound as a drug against TB. Rather, these and the preceding
experiments were merely intended to reveal and highlight the
feasibility of targeting relevant host factors, as an alternate strategy
for the chemotherapy of TB.
Discussion
Recent years have witnessed a resurgence of efforts directed at
tuberculosis (TB) drug research and development. This has been
spurred by the increasing incidence of drug resistance in the
infected population, engendering an urgent need for the
development of improved regimens for TB treatment. Although
drug resistant - particularly multi- and extremely-drug resistant -
TB poses a daunting challenge, the situation is further complicated
by the predominance of latent and/or persistent forms of TB
infection in the population [20]. These latter infections are
characterized by phenotypic resistance - or tolerance - to drugs,
despite being genotypically sensitive to them [20]. Indeed, latent/
persistent infection constitutes over ninety nine percent of the TB
infected population worldwide [20].
Conventional approaches to drug research have targeted unique
processes or enzymes of the pathogen. However, despite its many
successes, this approach suffers from the risk of generating newer
variants exhibiting drug resistance [21]. Further, this strategy is
also limited by its inability to address infection states where the
pathogen is metabolically less active such as in persistent or latent
infections. This issue is especially relevant in the case of Mtb
infections. An alternate paradigm for drug discovery has recently
emerged, at least for intracellular pathogens [22]. This is based on
the fact that the survival of an intracellular pathogen in the hostile
cellular environment requires it to exploit and subvert various host
factors. Therefore, identifying - and then targeting – such host
factors should provide an additional route for the therapeutic
management of these infectious diseases. Here, the anticipations
also are that such a strategy will be less likely to induce microbial
resistance [22].
To explore the possibilities offered by this avenue, siRNA-based
screens are now being widely employed to identify such host
factors for a range of viral, bacterial, and parasitic infections
[23,24,25,26,27,28,29]. In this connection, a recent screen of the
human kinome identified a kinase cluster around protein kinase B
(PKB) as being obligatory for the intracellular survival of Salmonella
typhimurium [30]. Interestingly, while inhibitors of PKB were
effective against this pathogen, they were also capable of partially
inhibiting infection of human macrophages with a strain of MDR-
Mtb. We, therefore, undertook the present study to further explore
the potential of such an approach in the specific context of Mtb.
Our siRNA screen successfully identified several host factors
involved in the regulation of H37Rv survival within the milieu of
the host macrophage. Interestingly, this group of target proteins
included those that facilitated, as well as those that impeded Mtb
survival. While a mechanistic resolution of the biochemical
pathways involved is clearly needed, this identification of
molecular components with opposing functional roles strongly
supports the existence of a host-specified axis that regulates the fate
of intracellular Mtb. Such an axis probably reflects the level of
equilibrium achieved between the intracellular processes initiated
to eliminate the infection, and the pathogen-mediated manipula-
tion of the host machinery in its own favor [31]. In this connection,
determined at 72h as described for Figure 2. For each of the isolates (indicated on the right) the results for treatment of infected cells either with
vehicle only (Mock), or with D4476 (50 mM, Inhibitor) is shown (indicated on the left side of the panel). Images shown for each of these groups are
those obtained for PHK67-labeled Mtb (Mycobacterium), acidified lysosomes (Lysotracker), or a merge of the two (Merge). The numbers indicate
overlap coefficient of the bacteria with the lysotracker and were obtained as described for Figure 2. Panel D depicts the growth profiles of the three
Mtb isolates obtained either in the absence, or presence of 50 mM D4476. At a final concentration of 10 mM, D4476 inhibits the activities of purified
CSNK1 and TGFbRI by .90 and 78% respectively [16]. Panel E compares the efficacies of the TGFbR and CSNK1 dual inhibitior D4476 with that of
either the TGFbR-specific inhibitor LY364947, or the CSNK1-specific inhibitor IC261. The doses used for each inhibitor was in terms of multiples of
their respective IC50 values as indicated, and the procedure employed was identical to that described for Panel A. Values are the mean (6 S.D.) of
three separate determinations.
doi:10.1371/journal.ppat.1000839.g006
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it is pertinent to note that previous studies have identified several
host proteins that play an important role during the course of an
Mtb infection. However, with the exception of a few examples
[32], the majority of these proteins are involved in processes that
occur either during, or soon after, the endocytic uptake of Mtb.
Thus, for example, the role of the calcium signaling pathway-
involving PI3K, PKB, CaMKII and Coronin 1 – in regulating
endocytosis and subsequent fusion of phagosomes with lysosomes
has been well studied [1,12]. Similarly, there is also information
available on the biochemical pathways that mediate microbicidal
responses of the infected macrophage [33]. In contrast to these
early responses, however, our screen was designed to specifically
capture those host molecular components that are involved in the
later time window of the infection process. That is, in the window
where the pathogen is either in the process of establishing, or has
established, a dynamic equilibrium with the intracellular machin-
ery of the host cell. Consequently, our present study examined a
relatively less explored facet of macrophage infection by Mtb and,
therefore, identified several novel host molecules whose role in
regulating intracellular Mtb has not been hitherto suspected. From
the standpoint of targeting host factors as a drug development
strategy for TB, we believe that it is such factors that regulate the
maintenance of an established infection that would be more
relevant.
An important aspect of our studies was the additional filtration,
of the identified H37Rv-specific host factors, against MDR-Mtb
variants that not only exhibited altered drug-sensitivity profiles,
but also altered properties of intracellular growth. Interestingly, a
significant proportion of these factors could be validated against
the other rapidly growing strain, 1934. In contrast, only a small
subset of these targets retained efficacy against JAL2261, a strain
whose levels did not significantly increase within infected cells.
These differences are consistent with at least a priori expectations
that the extent of cross-regulatory interactions between host and
pathogen would correlate directly with state of replication activity
of the pathogen.
The net outcome of our experiments was the identification of a
core list of host targets that were involved in regulating survival of
Mtb, independent of variations in either drug sensitivity profiles or
growth properties in the host cell. Further, we could also
demonstrate, at the level of ‘proof of principle’, that at least some
of these host factors may provide novel targets for the development
of anti-TB drugs. This was exemplified by our findings that the
simultaneous inhibition of TGFbRI and CSNK1 substantially
inhibited intracellular survival of both drug-sensitive and multiple
drug-resistant strains of MTB. In addition to J774.1 cells, this
effect was also observed in primary murine macrophages. More
importantly though, our experiments involving D4476 adminis-
tration to H37Rv-infected mice also provided in vivo validation for
the possibility of targeting host factors as a possible approach for
TB therapy. Here, it will be important to test the potential
applicability of the remaining host factors identified by our screen
in this regard. Further, the mechanism by which inhibition of
TGFbRI and CSNK1 induces elimination of the infection is also
of interest.
Thus, in summary, our present results highlight the existence of
host factors that regulate the intracellular survival of Mtb in a
manner that is insensitive to variations in either the drug-sensitivity
profile, or the intracellular growth properties. In addition, we also
provide proof-of-concept demonstration that targeting at least
some of these molecules can provide an alternate approach for the
chemotherapy of TB. Again as demonstrated here, a highlight of
such a strategy would be that it holds the promise of eventually
being able to develop suitable drugs that function in a manner that
is independent of the phenotypic and genotypic diversification
exhibited by Mtb in the field [20]. However, further validation in
the context of human infections will be necessary before such a
promise can be realized. Further, the issue of possible toxicity to
the host cell - as a result of inhibition of key host molecules - may
also require to be addressed.
Methods
A detailed description of all the experimental protocols
employed, and the standardization procedures are provided in
the Text S1.
Ethics statement
All animal experiments were carried out in accordance with
guidelines approved and created by the ICGEB animal ethics
committee.
Animals
Female BALB/c mice 4–6 wk of age kept in pathogen free
environment. TGFbRDN (TGFb receptor dominant negative,
BALB/C background) mice, 6 to 8 weeks of age, were purchased
from Jackson Laboratory, Bar Harbor, Maine. These mice were
maintained and breed in a specific-pathogen-free biosafety level-3
facility.
Figure 7. Efficacy of D4476 in the murine model of Mtb infection. Groups of naive mice (Female BALB/c mice 4–6 wk of age at 4/group) were
infected with 16106 M. tuberculosis H37Rv via the tail vein. One group of mice was sacrificed 24 h later and lung homogenates were plated onto
7H11 agar plates for confirming infection. At ten days post infection, compound D4476 at either 2 nmol/g (1) or 4 nmol/g of body weight (2) was
injected into the tail vein of mice for treatment. The i.v. injection was repeated on seventh day of treatment. In addition the inhibitor was also given
intraperitoneally on the third, fifth, tenth and twelfth day after initiation of treatment. Here, a parallel group of mice received an identical treatment
regimen with the vehicle only (Control). At fourteen days following treatment, mice were sacrificed and lung enriched using a homogenizer. An
aliquot of the homogenate was lysed and plated onto 7H11 agar plates in serial dilutions for determining the mycobacterial load. The results are
shown as mean (6 SD) CFU values in panel A. This experiment was also repeated with the higher dose of D4476 (i.e. with 4 nmol/g of body weight
with 4 mice/group). Here, the mean CFU values (6 SD) obtained for the Control (vehicle only) and the D4476-treated groups were 6861.46103 and
8.061.86103 respectively. Panel B shows the results of a similar experiment performed in mice that were infected with H37Rv through the aerosol
route as described in Methods. Here 8 mice were used in each group and the values (mean 6 S.D.) obtained in lung homogenates at 5 weeks after
infection are shown. Here again the control group was that which received the vehicle only (i.e. DMSO) in parallel with D4476 administration in the
other groups. Shown in Panel C are the mean (6 S.D.) weight of the spleens obtained from either uninfected mice (Uninfected), infected mice
without any inhibitor treatment (Control), or infected mice treated with either 2 (1) or 4 (2) nmol/g of body weight of D4476. These spleens are from
the experiment described in Panel B. For panels A to C the p values for individual differences are indicated. Panel D shows lung sections of infected
mice stained with hematoxylin / eosin 24 days after infection at610 (a) and640 (b). The typical pathology associated with experimental tuberculosis
infection in mice is seen. Multiple well-formed epithelioid cell granulomas with mantle of lymphocytes are seen (indicated by the arrows). In contrast,
mice treated with D4476 (160mg/kg body weight) maintained almost normal lung architecture610 (d),640 (e) with non-specific inflammation, and
no granuloma formation was observed in the lungs of these mice. Further, untreated mice reveal large number of acid-fast bacilli when visualized at
1006 (c) (indicated by the arrows); whereas very few bacilli were observed in mice treated with D4476 (4 nmol/g body weight) (f).
doi:10.1371/journal.ppat.1000839.g007
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Cells and culture
Murine macrophage cell line J774.1 (American Type Culture
Collection) was used in this study. J774.1 cells were cultured in
RPMI 1640 (Gibco Laboratories) supplemented with 10% FCS
(Hyclone) and were maintained between 2 and 106105 cells per
mL at 37uC in a humidified, 5% CO2 atmosphere. Before
infection cells were plated in 96 well plates at 2.56104 cells per
well overnight.
siRNA library
Mouse Phosphatase siRNA set V 1.0 and Mouse kinase siRNA
set V 1.0 library from Qiagen (two siRNAs/target) were used for
the study. For validation experiments siRNAs against the kinases
were obtained from Sigma siRNA (MISSION siRNA Mouse
Kinase Panel, three siRNAs/target), whereas the phosphatase-
specific siRNAs were procured from Dharmacon (SMARTpool)
(four siRNAs/target).
Infection of cells and the siRNA screen
J774.1 cells (25,000 cells/well in 96-well plates) were infected
with mycobacteria at an MOI ,10 (10 bacteria /cell, Figure S2).
After 4h, infected cells were washed twice with warm RPMI and
treated with gentamicin (100 mg/ml) for 2h to remove any
remaining extra cellular bacteria, and then in complete RPMI
containing 10 mg/mL gentamicin for the rest of the experiment.
These cells were then transfected with siRNA at a final
concentration of 100nM using hiperfect transfection reagent
(Qiagen) according to manufacturer’s protocol. At 48h a second
siRNA treatment was performed (see Text S1), and the cells
cultured for an additional 36h (i.e. a total culture period of 90h
after initiation of infection). At this point cells were solubilized in
50 mL of 0.06% SDS (in 7H9 medium), and CFUs determined
using either the undiluted lysate, or from lysate dilutions of 1:10, or
1:100. Each siRNA pool was evaluated in duplicate and the mean
of the CFU values, obtained at the two cell lysate dilutions was
determined. Each 96-well plate also included six negative control
wells. In two of these cells were treated with scrambled siRNA
following infection, whereas another two included infected cells
that were transfected with GFP-specific siRNA. In the remaining
two wells, infected cells were treated only with the transfection
reagent (Hiperfect). The mean CFU count obtained from all of
these six wells, in each 96-well plate, was taken as the control value
for that plate for determining the effects of target-specific siRNAs.
The standard deviation (SD) for the control values was also
calculated. A cut off of two SD from the mean value of control
wells was employed to designate the effects of a given siRNA
treatment as significant. The ‘hits’ obtained from this primary
screen were then further validated with siRNA pools obtained
from alternate sources as described above. Here, ‘hits’ were
confirmed on the basis of the percent change in CFUs from the
mean control value, in addition to an SD cut off value of two. That
is, an increase or decrease of 50% from the control value for an
siRNA with the additional caveat that this deviation from the
mean control value was greater than 2SD was selected as validated
(see Fig. 1). The validation exercise involved two separate
experiments, whereas the subsequent comparison of the effects
of the validated siRNA pools in cells infected with H37Rv, with
that in cells infected with 1934 and JAL2261 was also ascertained
in two additional independent experiments.
RNA isolation and microarray analysis
In two separate experiments, cells were plated in six-well plate
(26106 cells per well) and infected with H37Rv as described
above. At 16h, 48h, and 96h later these, and uninfected, cells were
lysed and RNA was isolated with trizol. One-color microarray-
based gene expression analysis was performed by hybridizing
against a mouse whole genome array consisting of probes for
44,000 genes (Agilent).
Confocal microscopy
Bacteria were stained using the membrane stain PKH67
(Sigma) according to the manufacturer’s protocol. J774.1 cells
were seeded onto #1 thickness, 12 mm diameter glass cover-slips
pre-coated with fibronectin in 24-well tissue culture plates at a
density of 0.076106 cells per cover-slip, respectively and infected
with stained bacteria using the protocol as described above. Cells
were incubated with 100nM Lysotracker during the last hour of
the 72 hr chase at 37uC and then fixed with 4% para-
formaldehyde (Sigma). The cover slips were washed thoroughly
with PBS and were mounted on slides with Antifade (Biorad).
Stained cells were observed with a Nikon TE 2000E laser scanning
confocal microscope equipped with 606/1.4 NA PlanApochromat
DIC objective lens, and the extent of bacterial co-localization with
acidified lysosomes was determined as the Overlap Coefficient (see
Text S1).
Infection of mice
Groups of naive mice (Female BALB/c mice 4–6 wk of age at
4/group) were infected with 16106 M. tuberculosis H37Rv via the
tail vein. One group of mice was sacrificed 24 h later and lung
homogenates were plated onto 7H11 agar plates for confirming
infection. At ten days post infection, compound D4476 a final
concentration of either 25 mM or 50 mM was injected into the tail
vein of mice for treatment. The i.v. injection was repeated on
seventh day of treatment. In addition the inhibitor was also given
intraperitoneally on the third, fifth, tenth and twelfth day after
initiation of treatment. At fourteen days following treatment, mice
were sacrificed by carbon dioxide narcosis.
For experiments involving the aerosol route of infection, mice (8
per group) were infected with H37Rv by delivering between 100–
150 bacteria per lung – as determined by the culture of lung
homogenates at 24 h later - during 30 min of exposure. At the
relevant times after infection, mice were sacrificed by carbon
dioxide narcosis. The lungs were perfused and removed aseptically
and weighed. The lungs were then homogenized and dilutions of
these homogenates were plated on 7H11 agar plates for
subsequent enumeration of the CFU.
Supporting Information
Text S1 Supplementary Methods
Found at: doi:10.1371/journal.ppat.1000839.s001 (0.05 MB
DOC)
Figure S1 Effect of D4476 on the intracellular growth of
mycobacteria in primary mouse macrophages. Panel A shows the
growth profiles of the indicated strains of Mtb in peritoneal mouse
macrophages. The protocol employed here was identical to that
described for Figure 3C in the main text. For the experiment in Panel
B, macrophages independently infected with the three mycobacterial
strains were treated with three rounds of addition of either the vehicle
only (Control), or with D4476 at a final concentration of 50mM.
Additions were performed at 16, 40 and 64h post-infection. The CFU
values obtained are expressed as a % of that in the control group and
values are mean (6SD) of three experiments. Panel C shows extent of
co-localization of PHK67-stained mycobacteria with acidified
lysosomes (stained with Lysotracker) at 72h as described for
Figure 2. For each of the isolates (indicated on the right) the results
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for treatment of infected cells either with vehicle only (Mock), or with
D4476 (50 mM, Inhibitor) is shown (indicated on the left side of the
panel). Images shown for each of these groups are those obtained for
PHK67-labeled Mtb (Mycobacterium), acidified lysosomes (Lyso-
tracker), or a merge of the two (Merge).
Found at: doi:10.1371/journal.ppat.1000839.s002 (1.80 MB TIF)
Figure S2 Infection of J774.1 cells infected with H37Rv. J774.1
cells were infected with H37Rv labelled with PKH67 at an MOI
of 10 as described in Methods). Panels A, B and C show confocal
image of J774.1 cells after 24, 36, and 72 hours of infection
respectively. Serial confocal sections (0.5 mm thick) within a z-stack
spanning a total thickness of 10–12 mm were taken in green and
transmission channels simultaneously, using the motor drive
focusing system. More then 150 cells were analysed. The merged
pictures of single confocal planes are shown.
Found at: doi:10.1371/journal.ppat.1000839.s003 (5.78 MB TIF)
Figure S3 Efficiency of siRNA transfection and the resultant
silencing of expression of target proteins in J774.1 cells. J774.1
cells were transfected with AllStars Negative Control siRNA,
Alexa Fluor 488 Labeled (RNAi Human/Mouse starter kit,
Qiagen) at a 10nM concentration using hiperfect transfection
reagent (according to manufacturer’s protocol). Cells were fixed at
6h and 36h post-transfection. Panel A and B shows the J774.1 cells
after 6 and 36 hours of transfection respectively. Fixed cells were
imaged by confocal microscope as described for Figure S2. Panel
C shows the Western blot data obtained after transfection of
J774.1 cells with specific siRNA to monitor protein knock-down.
siRNA transfection conditions were the same as that used in the
screen and samples were collected at 24, 36, 48 and 72 hours post-
transfection. At these times, cells were lysed and proteins resolved
by SDS-PAGE followed by immuno-blotting against the target
protein. In these gels, GAPDH and/or PLCc2 were also probed to
serve as the loading control. Panel D shows the extent of siRNA
mediated knock-down for representative proteins from the list of
validated hits in H37Rv infected J774.1 cells. Here infected cells
were transfected with the relevant siRNA as described for our
screening protocol (Methods) and protein levels measured by
Western blot in cell lysates obatined at 48 hours. For TGFbRI,
and CSNK1d results obtained with siRNA pools employed both in
the primary (1) and validation (2) screen are shown. Panel E show
the dose-dependent effects of siRNA treatment for TGFbRI and
CSNK1d. Panel F shows the effects of variations in the extent of
TGFbRI silencing, on the pathogen load. Infected cells were
treated with the indicated doses of TGFbRI-specific siRNA, and
the consequences on intracellular mycobacteria load was the
determined. Results expressed in terms of % reduction in CFU
obtained, from that in infected cells treated with GFP-specific
siRNA. Panel G compares the extent of silencing between the pool
of two siRNA employed in the primary screen (Pool), and the
individual constituents of the pool (Oligo 1 and Oligo 2). Results
for both CSNK1d and TGFbRI are shown.
Found at: doi:10.1371/journal.ppat.1000839.s004 (5.25 MB TIF)
Table S1 Screening Data for Kinase-Phosphatase siRNA
Library. Primary screening data for H37Rv survival in J774.1 cells
is presented in sheet 1 of Table S1. siRNA against each target gene
was tested in duplicate, and data readings were obtained at two
different dilutions for each. Here, we took care to ensure that both
sets of the duplicate were not placed in adjacent wells of the plate.
Instead, they were widely separated either across the wells of a
given plate, or between two separate plates. Data for the two
replicates are shown as CFU1 and CFU2 (6103). The column
control mean 1 and control mean 2 represents average control
readings for each individual set, while SD1 and SD2 are their
respective standard deviations. There are more than one control
values for some plates because the whole plate was not set up at the
same time in many instances. Deviation 1 and Deviation 2 are
deviation of individual values from the control mean in terms of
respective fold SD. Only those siRNAs giving an average deviation
of value greater than 2 (positive or negative) in both replicates was
taken to the next step for revalidation using siRNA sequences from
a different source. While selecting average deviation greater than 2,
we noticed that many of them showed large deviation between the
two individual deviations. Nonetheless, they were also included in
the primary hit list in order to avoid false negatives. Many spurious
selections at this stage would later get filtered out in the revalidation
due to more stringent selection criteria (more than 50% increase or
decrease from the control). More than 50% criteria is stringent
because most of the times the SD for a control value ranged
between 10–20% of control mean, thereby selecting even those
genes where the effect was less than 50%. Sheet 2 of the table
contains the list of validated hits along with their values (percent
reduction for both primary and validation, while average CFU for
validation) and siRNA sequences used for validation experiment.
For some genes for which siRNAs were not available in Sigma
library (pool of three, columns F, G and H), we used siRNA pools
from Dharmacon (pool of four, columns F, G, H and I).
Found at: doi:10.1371/journal.ppat.1000839.s005 (0.29 MB XLS)
Table S2 Cell Viability by MTT assay. Viability of H37Rv-
infected and uninfected J774.1 cells was assessed at 90 hours after
treatment with the siRNA pools for the 41 validated targets by the
MTT assay (detail protocol in Methods). The average value for the
MTT assay (mean of three) along with fold SD deviation from the
control mean is shown for both infected and uninfected condition.
Found at: doi:10.1371/journal.ppat.1000839.s006 (0.02 MB PDF)
Table S3 Functional Class and disease association of ‘Hits’.
‘Hits’ identified in this study were searched extensively for their
various GO class association, thereby summarizing the potential
set of biological functions that they may be involved in regulating.
We also examined for any known disease association for these
‘hits’ and this information is included in the table.
Found at: doi:10.1371/journal.ppat.1000839.s007 (0.04 MB XLS)
Table S4 Gene expression data for the validated targets. Hits
filtered out after validation was checked for their expression level
in J774.1 cells using one-color microarray-based gene expression
analysis performed by hybridizing against a mouse whole genome
array consisting of probes for 44,000 genes (Agilent). Values equal
to or above 100 are considered as expressed. Expression levels
were monitored at 16, 48 and 96 hours post infection.
Found at: doi:10.1371/journal.ppat.1000839.s008 (0.03 MB PDF)
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